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Case Report 
Reactive Hypertrophy of an Accessory Spleen
Mimicking Tumour Recurrence of Metastatic Renal
Cell Carcinoma
Christin Tjaden, Jens Werner, Markus W. Buechler and Thilo Hackert, Department of Surgery, 
University of Heidelberg, Heidelberg, Germany.
De novo occurrence of an accessory spleen after splenectomy is worth noting for two reasons. First, it is
known that splenectomy can cause reactive hypertrophy of initially inactive and macroscopically invisible
splenic tissue. Second, it can mimic tumour recurrence in situations in which splenectomy has been per-
formed for oncological reasons. This might cause difficulties in differential diagnosis and the clinical
decision for reoperation. We report the case of a patient with suspected recurrence of renal cell carcinoma
after total pancreatectomy and splenectomy for metastatic renal cell carcinoma, which finally revealed an
accessory spleen as the morphological correlate of the newly diagnosed mass in the left retroperitoneum.
[Asian J Surg 2011;34(1):50–52]
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Introduction
The pancreas is a common site of metastases from renal
cell carcinoma (RCC) of the left kidney, which are often
located in the tail of the gland and can be treated by pan-
creatic resection with curative intent.1 Usually, distal 
pancreatectomy for oncological indications includes
splenectomy.2 During follow-up examination of the
patients computed tomography (CT) or magnetic reso-
nance imaging scan is performed to detect tumour recur-
rence or liver metastases.3 Sometimes, it is not possible to
differentiate recurrence or metastases from other processes
by these radiological methods. Here, we report the case of
a patient with suspected recurrence of RCC after total
pancreatectomy and splenectomy, which led to a reopera-
tion with tumour extirpation, and finally revealed an
accessory spleen as the correlate of the newly diagnosed
mass in the left retroperitoneum.
Case report
A 69-year-old patient with a history of left-sided RCC and
tumour nephrectomy 11 years before underwent total
pancreatectomy and splenectomy because of multiple
pancreatic metastases of the RCC. Twenty months after
resection, CT revealed a new tumour-suspicious soft 
tissue mass (diameter, 2 cm×3 cm) that was located in the
left upper retroperitoneal space (Figure 1). Staging by
chest CT, bone scintigraphy and positron emission tomog-
raphy revealed no further tumour manifestation. The
patient underwent exploratory laparotomy under the sus-
picion of tumour recurrence. Abdominal exploration
showed no hepatic or peritoneal metastases. The tumour
was removed in toto oncologically by wide excision that
included the surrounding soft tissue, without prepara-
tion along the tumour itself. During the postoperative
course, the patient recovered quickly and was discharged
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7 days after the operation. Histological examination of the
specimen revealed splenic tissue without any tumourous
aspect of the RCC. It was therefore interpreted as an
accessory spleen that became reactively hypertrophic as a
consequence of the splenectomy that had been performed
20 months before. At 48-month follow-up, the patient
showed no signs of tumour recurrence.
Discussion
The pancreas is a frequent site for RCC metastases, espe-
cially of the left kidney. These metastases can be treated
with a curative approach by distal or total pancreatectomy,
with good long-term results.1 Usually, total splenectomy
is performed together with distal pancreatectomy for
oncological indications.2 Although the spleen does not
have an immunological function in elderly patients, reac-
tive hypertrophy of an initially unrecognized accessory
spleen has been described in haematological patients with
thrombotic or immune thrombocytopenic purpura after
splenectomy. In these patients, occurrence of an accessory
spleen can cause relapse of the disease,4,5 which requires
removal of the accessory organ. The existence of an acces-
sory spleen is a relatively common congenital finding that
is seen in 10–30% of patients at autopsy.6 Accessory spleens
are mainly located within the hilar region of the spleen,
along the splenic artery, inside the pancreas or the omen-
tum, and are usually asymptomatic unless underlying
haematological diseases with reactive hypersplenism are
present. Enlargement, and therefore visibility of accessory
spleens after splenectomy, which imitate neoplastic lesions,
as observed in our patient, can occur in the region of the
removed spleen, the liver or the adrenal gland.6 This is
understood as reactive hypertrophy of congenitally dislo-
cated tissue, but its mechanisms remain unclear.
In the present case, no evidence of an accessory spleen
was visible at the time of pancreatic resection for the RCC
metastases, nor in follow-up imaging. Therefore, the newly
diagnosed mass in the left retroperitoneal space was pri-
marily suspected as tumour recurrence. This diagnosis
was found by CT imaging (Figure 1). Contrast-enhanced
CT has a sensitivity of 39–100% to detect solid intra-
abdominal and retroperitoneal lesions or liver metastases.7
With regard to the present case, it needs to be considered
that RCC metastases and accessory spleens show early
arterial phase enhancement of contrast medium, which
makes differentiation between both entities difficult.8,9
Magnetic resonance imaging as an equivalent imaging
tool can also be recommended for tumour follow-up
examination, but it is not available everywhere and is
more expensive than standard CT.3 To improve diagnos-
tic accuracy, radionuclide imaging has been introduced
into the clinical routine.7,9 In case of suspected accessory
splenic tissue, Technetium-99m heat-damaged red blood
cell scintigraphy with single positron emission computed
tomography/CT is the gold standard.10 This tool should
be considered in the diagnostic work-up whenever the
possibility of an accessory spleen is taken into account. In
the case presented here, no additional investigations were
performed, because the diagnosis of tumour recurrence
seemed reasonable due to localization and phase-specific
contrast enhancement.
In conclusion, our case demonstrates the difficulties
that can arise from newly occurring solid masses during
tumour follow-up examinations. No diagnostic tool can
definitely differentiate tumour recurrence or metastases
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Figure 1. Computed tomography scan showing the initial regular follow-up at 12 months (left) and 20 months (right) with the newly
diagnosed solid tumor-suspicious mass in the left retroperitoneum (white circle).
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from other processes, for example, an accessory spleen.
Radionuclide imaging can clarify lesions that are unde-
fined by conventional cross-sectional imaging. In the case
of a newly occurring intra-abdominal mass after splenec-
tomy, an accessory spleen should be considered when
evaluating reoperation.
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